How does light therapy work?

Light interfaces with immune biology through two complementary routes:

• Systemic immune signaling:
  Timed red-light exposure (≈ 620–635 nm) can modulate circulating inflammatory mediators and systemic cytokine networks (Marashian et al., 2022). Complementary preclinical work using amber-range LEDs (≈ 590–630 nm) demonstrated direct effects on macrophage and lymphocyte polarization, balancing pro- and anti-inflammatory states (de Brito Sousa et al., 2024).
  

Together, these mechanisms suggest a coordinated approach: regular red or near-infrared light therapy exposure to help balance systemic immune tone, and localized PBM applications to calm inflammation and restore tissue integrity - kept within an informational, wellness context.

Applications for immune system

Light therapy can complement conventional care for a wide range of persistent complaints:

• Systemic inflammation and recovery:
  A randomized clinical trial using 620–635 nm LED PBM in COVID-19 patients showed significant reductions in IL-6 (–82 %), IL-8 (–54 %), and TNF-α (–82 %) within three days (Marashian et al., 2022).
  
• Joint and tissue inflammation:
  In rheumatoid-arthritis models, 610 nm LED PBM suppressed NF-κB and NLRP3 signaling, reducing synovial inflammation and joint swelling (Ryu et al., 2023).
  
• Immune-cell modulation:
  Amber-range LED light (≈ 590–630 nm) altered polarization markers in human monocytes and lymphocytes, suggesting direct regulatory effects on immune-cell behavior (de Brito Sousa et al., 2024).
  
• Whole-body immune resilience:
  A triple-blind RCT using full-body 660/850 nm LED PBM in fibromyalgia reported reduced chronic inflammation and improved quality of life, indicating systemic immune and metabolic support (Navarro-Ledesma et al., 2023).

Key benefits at a glance

• Balanced cytokine activity – Red LED PBM reduced IL-6, IL-8, TNF-α during acute inflammation (Marashian et al., 2022).
• Localized inflammation control – 610 nm LED PBM suppressed pro-inflammatory signaling in joint tissue (Ryu et al., 2023).
• Immune-cell regulation – Amber-LED exposure influenced monocyte and lymphocyte phenotypes (de Brito Sousa et al., 2024).
• Systemic resilience – Whole-body 660/850 nm LED PBM improved pain, energy, and inflammatory balance in chronic conditions (Navarro-Ledesma et al., 2023).

Note: Effects vary with spectrum, intensity, timing, and individual sensitivity; findings for PBM in immune contexts are evolving.

Who can benefit?

Individuals experiencing chronic low-grade inflammation, post-infection fatigue, autoimmune-related discomfort, or simply aiming to maintain immune balance during stress or seasonal changes.

How to use it in practice

Local application:
10–20 minutes, 3–5 times weekly, at a distance of 10–30 cm.

Target zones:
Areas with chronic discomfort, joint or muscle stiffness, or slow-healing tissues.

Consistency over intensity - regular use over weeks supports cumulative effects on pain, circulation, and repair.

Scientific context

Controlled studies indicate that LED PBM can shape immune signaling and inflammation:

• Significant cytokine reduction with 620–635 nm LED PBM in human subjects (Marashian et al., 2022)

• Anti-inflammatory and joint-protective effects at 610 nm in rheumatoid-arthritis models (Ryu et al., 2023)

• Monocyte and lymphocyte modulation by amber LED (de Brito Sousa et al., 2024)

• Systemic symptom and inflammation improvement with full-body 660/850 nm LED PBM (Navarro-Ledesma et al., 2023)

These studies inform light based practices and do not constitute therapeutic claims for redtreat devices.

Why redtreat

We focus on research-informed light patterns - bright light tools for mornings and gentle red/NIR options for local comfort - designed for ease, consistency, and high build quality.

• Timing-first design: morning bright-light options; evening low-blue options

• Targeted PBM (≈630–1060 nm) for localized comfort routines

• Swiss engineering for precision and reliability

Disclaimer

References are provided for educational and informational purposes. They summarize general research on light therapy. They do not constitute therapeutic or clinical claims for redtreat products. Products are not intended to diagnose, treat, cure, or prevent any disease. Individuals with ongoing symptoms or medical conditions should consult a healthcare professional.

Scientific references

• Marashian, S. M. et al. (2022). Photobiomodulation improves serum cytokine response in COVID-19 patients.
• Ryu, J. H. et al. (2023). 610 nm LED PBM attenuates inflammatory signaling in rheumatoid arthritis models.
• de Brito Sousa, K. et al. (2024). Amber LED effects on inflammatory and regulatory immune cells.
• Navarro-Ledesma, S. et al. (2023). Whole-body LED PBM reduces pain and inflammatory load in fibromyalgia.